TOTAL VOLUME:
$134b
24H VOL:
$107,351,958
24H TRANSACTIONS:
2,388,728,490
OPEN INTEREST:
$1,416,970,024
400,720
Markets across
30,097
events
MATCHED EVENTS:
2,633
PLATFORM COVERAGE:
5
Polymarket:
39%
VS.
Kalshi:
61%
Hantavirus vaccine in 2026?
- Polymarket
Hantavirus vaccine in 2026? - Polymarket
1W
News
Positive
Negative
Neutral
Hover marker for details
Vol.
·
Resolves Jan 1, 2027
Hantavirus vaccine in 2026?
$
Description
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Polymarket
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Frequently asked questions
Currently, prediction market odds suggest a relatively low probability of a Hantavirus vaccine being available by 2026. This contrasts with some analyst forecasts, which vary widely depending on the specific research pipeline and assumed funding levels. While some experts are optimistic about progress in mRNA vaccine technology potentially accelerating development, others point to the challenges of creating a broadly protective Hantavirus vaccine due to the diversity of strains. This market provides a real-time assessment of collective belief, which may differ significantly from individual expert opinions.
On Polymarket, this market is priced through a continuous auction mechanism where traders buy and sell shares representing their belief about the outcome. The price of a share directly reflects the implied probability of a Hantavirus vaccine being approved by 2026. As more traders participate and new information emerges, the price adjusts accordingly. On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. The market’s price is determined solely by supply and demand from traders on Polymarket, reflecting their aggregated assessment of the likelihood of success.
This market resolves around Jan 1, 2027, with the outcome confirmed once the event is verifiable from credible public reporting. Resolution will depend on whether a Hantavirus vaccine has received full regulatory approval from a major health authority (e.g., the FDA or EMA) and is demonstrably available for widespread use by the specified date. The determination will be based on publicly available information and established scientific consensus regarding vaccine efficacy and safety, not on any specific platform criteria.
Several key events could significantly impact this market. Positive Phase 3 clinical trial results for a Hantavirus vaccine candidate would likely cause a substantial price increase. Conversely, negative trial data, unexpected safety concerns, or a significant reduction in research funding could drive the price down. Regulatory updates from health authorities regarding vaccine approval pathways will also be closely watched. Breakthroughs in mRNA technology or the identification of broadly neutralizing antibodies could also shift market sentiment, as could any major outbreaks of Hantavirus infections.
